Early bladder cancer study using new drugs and BCG
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to voluntarily join and sign informed consent
- You are age 18 or older, and your general condition is good (ECOG 0–2)
- You need a diagnosis of high-risk NMIBC from prior bladder biopsy, and the bladder area should be fully removed or only carcinoma in situ remains
- You must be well enough for treatment (good organ function) and expected to live at least 2 years
- You must be able and willing to use effective birth control during treatment and for 3 months after (and pregnancy testing if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests two investigational drugs given together to treat high-risk non-muscle invasive bladder cancer that cannot be completely removed with standard surgery. The goal is to see if this combination can help control the cancer and avoid the need for bladder removal.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
Hear when a new High - Risk NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.